Forest Laboratories Expects 2010 Profit Boost

Tue, 04/21/2009 - 7:39am
NEW YORK (AP) — Drug developer Forest Laboratories Inc. said Tuesday it expects a profit boost in fiscal 2010, driven by sales of the Alzheimer's disease drug Namenda, while sales of the antidepressant Lexapro remain flat. The company expects profit between $3.45 and $3.55 per share on revenue of about $4.1 billion. In fiscal 2009, the company earned $2.52 per share on revenue of $3.92 billion. The fiscal year ends March 31. Analysts polled by Thomson Reuters expect profit of $3.47 on revenue of $4.18 billion in fiscal 2010. Forest Laboratories said it expects Lexapro sales to remain flat at about $2.3 billion and Namenda sales to rise 12 percent to $949.3 million. The drug developer also reported fourth-quarter profit plunged on a hefty charge for reserve funds related to federal allegations that it bribed doctors to prescribe antidepressants and pushed for their use in children.

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.